XBiotech USA, Inc. (XBIT)

Oncology Corporate Profile

Stock Performance

13.3900
-0.7600

HQ Location

8201 E Riverside Dr
Bldg 4 Ste. 100
Austin, TX 78744

Company Description

XBiotech is leading the commercialization of biological therapies, including the discovery and development of True Human™ antibodies. The Company's lead product candidate now in two unique Phase III registration studies represents a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and shorten lead times for development of biological drugs. New manufacturing technologies are at the heart of XBiotech's approach to next generation biological therapies, including the production of highly competitive biosimilar or biobetter products.

Website: http://www.xbiotech.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Xilonix®monoclonal (IgG1k) antibodyCancer cachexiaIII
Xilonix®monoclonal (IgG1k) antibodyColorectal cancerIII
Xilonix®monoclonal (IgG1k) antibodyNon Small Cell Lung Cancer (NSCLC)II

View additional information on product candidates here »

Source: http://www.xbiotech.com

Recent News Headlines

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/18/2017 12:19 pm

5/18/2017 12:19 pm

5/18/2017 12:19 pm

5/18/2017 12:19 pm

5/16/2017 12:19 pm

5/16/2017 12:19 pm

5/16/2017 12:19 pm

5/11/2017 06:19 am

5/11/2017 06:19 am

5/11/2017 06:19 am

5/10/2017 12:19 pm

5/4/2017 06:19 am

5/3/2017 12:19 pm

4/28/2017 06:19 am

4/21/2017 06:20 am

4/20/2017 12:19 pm

4/10/2017 06:17 am

4/10/2017 06:17 am

XBiotech Announces On-Time Submission to the EMA

3/27/2017 05:02 pm

[GlobeNewswire] - AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that it completed on time and confirmed receipt of its March 22, 2017 submission of responses to the remaining ...

XBiotech Announces On-Time Submission to the EMA

3/27/2017 05:01 pm

[GlobeNewswire] - AUSTIN, Texas, March 27, 2017-- XBiotech Inc. announced today that it completed on time and confirmed receipt of its March 22, 2017 submission of responses to the remaining EMA queries related to its marketing ...